Stereotactic Radiosurgery for Cranial and Peripheral Nerve Tumors

Dear Colleagues,

Central and peripheral nerve tumors are a heterogeneous group of mostly benign tumors that are rare in the general population. Certain categories of nerve tumors, including neurofibromas, schwannomas, and hemangioblastomas, occur sporadically within the population or in association with genetic disorders like neurofibromatosis (NF) and von Hippel–Lindau (VHL). Various benign neoplasms can occur in nerve sheaths, including neurofibromas, schwannomas, perineuriomas, hybrid nerve sheath myxomas, ganglioneuromas, and hemangioblastomas. Malignant tumors can also involve neural sheaths of the central or peripheral nervous system, like malignant peripheral nerve sheath tumors (MPNSTs), secondary neoplastic involvement of a neural plexus (brachial or lumbosacral), and neurolymphomatosis. These tumors are typically managed with medical management or surgery, but for unresectable or recurrent tumors, radiation can be a useful tool for local control. More sophisticated radiation techniques that are now available can utilize high radiation doses while maintaining the safety of nearby organs through the use of stereotactic radiotherapy (SRT). Improvements in imaging have also allowed more accurate delineation of various skull base and peripheral nerve tumors for stereotactic radiotherapy using fluorodeoxyglucose (FDG) PET/CT, multiparametric magnetic resonance imaging (MRI), and gallium-68 DOTATATE PET imaging.

This Special Issue will explore the use of stereotactic radiotherapy in the treatment of benign and malignant nerve tumors.

We are looking for manuscripts focusing on the use of advanced imaging and radiosurgery in the treatment of various benign and malignant nerve tumors within the brain, spine, and peripheral nerves.

Dr. Joshua D. Palmer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cranial nerve tumors
• stereotactic radiotherapy
• Gamma Knife radiosurgery
• stereotactic ablative radiotherapy (SABR)
• proton therapy
• neurosurgery
• schwannoma
• neurofibroma
• malignant peripheral nerve sheath tumor
• paraganglioma